HUP0100012A3 - Use for macrolides for the treatment of cancer and macular degeneration - Google Patents

Use for macrolides for the treatment of cancer and macular degeneration

Info

Publication number
HUP0100012A3
HUP0100012A3 HU0100012A HUP0100012A HUP0100012A3 HU P0100012 A3 HUP0100012 A3 HU P0100012A3 HU 0100012 A HU0100012 A HU 0100012A HU P0100012 A HUP0100012 A HU P0100012A HU P0100012 A3 HUP0100012 A3 HU P0100012A3
Authority
HU
Hungary
Prior art keywords
macrolides
cancer
treatment
macular degeneration
macular
Prior art date
Application number
HU0100012A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of HUP0100012A2 publication Critical patent/HUP0100012A2/hu
Publication of HUP0100012A3 publication Critical patent/HUP0100012A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
HU0100012A 1997-10-31 1998-10-30 Use for macrolides for the treatment of cancer and macular degeneration HUP0100012A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96147397A 1997-10-31 1997-10-31
PCT/US1998/023043 WO1999022722A2 (fr) 1997-10-31 1998-10-30 Utilisation de macrolides pour le traitement du cancer et de la degenerescence maculaire

Publications (2)

Publication Number Publication Date
HUP0100012A2 HUP0100012A2 (hu) 2001-05-28
HUP0100012A3 true HUP0100012A3 (en) 2003-07-28

Family

ID=25504514

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0100012A HUP0100012A3 (en) 1997-10-31 1998-10-30 Use for macrolides for the treatment of cancer and macular degeneration

Country Status (17)

Country Link
EP (1) EP1027060A2 (fr)
JP (1) JP2001521891A (fr)
KR (1) KR20010031577A (fr)
CN (1) CN1278178A (fr)
AR (1) AR043071A1 (fr)
AU (1) AU1206799A (fr)
BG (1) BG104436A (fr)
BR (1) BR9813318A (fr)
CA (1) CA2307850A1 (fr)
HU (1) HUP0100012A3 (fr)
IL (1) IL135518A0 (fr)
NO (1) NO20002189L (fr)
PL (1) PL340604A1 (fr)
SK (1) SK6172000A3 (fr)
TR (1) TR200001147T2 (fr)
WO (1) WO1999022722A2 (fr)
ZA (1) ZA989885B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4858801A (en) 2000-04-13 2001-10-30 Biotica Tech Ltd Hybrid glycosylated products and their production and use
DK1539157T3 (da) 2002-09-18 2013-10-07 Univ Pennsylvania Fremgangsmåde til hæmning af choroidal neovaskularisering
TW200420573A (en) 2002-09-26 2004-10-16 Rib X Pharmaceuticals Inc Bifunctional heterocyclic compounds and methods of making and using same
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
US7943800B2 (en) 2003-03-28 2011-05-17 Sloan-Kettering Institute For Cancer Research Migrastatin analogs and uses thereof
US7083802B2 (en) 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
KR20060085246A (ko) 2003-09-18 2006-07-26 마커사이트, 인코포레이티드 경공막 전달
US7083803B2 (en) 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
US7087237B2 (en) * 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
EP1723159B1 (fr) * 2004-02-27 2019-06-12 Melinta Therapeutics, Inc. Composes macrocycliques et leurs procedes de fabrication et d'utilisation
CN108101948A (zh) * 2004-02-27 2018-06-01 瑞伯-X医药品有限公司 大环化合物以及其制作和使用方法
JP5149001B2 (ja) 2004-05-25 2013-02-20 スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ 癌の処置におけるマイグラスタチンアナログ
US8188141B2 (en) 2004-09-23 2012-05-29 Sloan-Kettering Institute For Cancer Research Isomigrastatin analogs in the treatment of cancer
DK1848431T3 (en) 2005-02-09 2016-04-18 Santen Pharmaceutical Co Ltd LIQUID FORMULATIONS FOR TREATMENT OF DISEASES OR CONDITIONS
EP1904056B1 (fr) 2005-07-18 2009-04-29 Minu, L.L.C. Utilisation d'un macrolide pour restaurer la sensation cornéenne
EP1934237A2 (fr) 2005-08-24 2008-06-25 Rib-X Pharmaceuticals, Inc. Triazoles et procedes de production et d'utilisation de ces composes
EP3290427A1 (fr) 2005-08-24 2018-03-07 Melinta Therapeutics, Inc. Systèmes à trampoline et procédés de fabrication et d'utilisation de ceux-ci
KR20140093764A (ko) 2006-02-09 2014-07-28 산텐 세이야꾸 가부시키가이샤 안정한 제제와 그 제조 및 사용 방법
ES2563288T3 (es) 2006-03-23 2016-03-14 Santen Pharmaceutical Co., Ltd Rapamicina en dosis bajas para el tratamiento de enfermedades relacionadas con la permeabilidad vascular
CN106317146B (zh) * 2015-06-18 2019-06-21 沈阳药科大学 双环克拉霉素衍生物及其作为肿瘤细胞增值抑制剂的用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6461090A (en) * 1989-10-30 1991-05-02 Abbott Laboratories Injectable formulation for lipophilic drugs
US5498424A (en) * 1994-11-30 1996-03-12 Klein; Ira Method of treating obesity

Also Published As

Publication number Publication date
CA2307850A1 (fr) 1999-05-14
AU1206799A (en) 1999-05-24
ZA989885B (en) 1999-05-05
KR20010031577A (ko) 2001-04-16
AR043071A1 (es) 2005-07-20
PL340604A1 (en) 2001-02-12
NO20002189D0 (no) 2000-04-27
BR9813318A (pt) 2000-08-22
TR200001147T2 (tr) 2000-08-21
EP1027060A2 (fr) 2000-08-16
IL135518A0 (en) 2001-05-20
WO1999022722A2 (fr) 1999-05-14
JP2001521891A (ja) 2001-11-13
CN1278178A (zh) 2000-12-27
BG104436A (en) 2000-12-29
WO1999022722A3 (fr) 1999-08-05
NO20002189L (no) 2000-06-28
SK6172000A3 (en) 2001-03-12
HUP0100012A2 (hu) 2001-05-28

Similar Documents

Publication Publication Date Title
ZA989885B (en) Use of macrolides for the treatment of cancer and macular degeneration
PL347942A1 (en) Device for the treatment of macular degeneration
ZA979096B (en) Viral and cancer treatment
ZA957483B (en) Compounds and methods for the treatment of cancer
AU2072201A (en) Agents and methods for the treatment of proliferative diseases
AU2212299A (en) Compositions and methods for the treatment of tumor
IL127739A0 (en) Retinoyloxy (substituted) alkylene butyrates useful for the treatment of cancer and other proliferative diseases
HUP0102473A3 (en) Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases
AU2476200A (en) Ribozyme therapy for the treatment and/or prevention of restenosis
IL143212A0 (en) Compositions and methods for the treatment of tumor
IL141426A0 (en) Compositions and methods for the treatment of tumor
AU8068198A (en) Methods for treating human cancers
AU2529799A (en) Benzofuran-4-carboxamides and their therapeutic use
AU6288698A (en) Apparatus for stimulating the human body
GB9819999D0 (en) Treatment of cancer
ZA984650B (en) Intratumoral administration of triphenylethylenes for the treatment of cancer
HK1031326A (en) Use of macrolides for the treatment of cancer and macular degeneration
AU6653698A (en) Use of the p-ten suppressor gene in diagnosis and treatment of cancer
GB9828564D0 (en) Materials and methods for the treatment and diagnosis of cancer
AU3205295A (en) Antisense oligonucleotides and methods for the treatment of schistosomiasis
AU6404698A (en) Treatment methods for obtaining therapeutic products and resulting products
AU4406899A (en) Progesterone treatment of cancer
ZA988293B (en) Compositions and methods for the treatment of tumor.
HK1036305A (en) Dnazymes and methods for treating restenosis
GB9703517D0 (en) Steroid treatment